程序性死亡受体 1 的检测方法及其在乳腺癌中表达的研究进展

In recent years, tumor immunotherapy has become a new anti-tumor therapy after surgery, radiotherapy, chemotherapy, endocrinotherapy, and targeted drug therapy. In particular, many of patients with non-small cell lung cancer, melanoma and other malignant solid tumors have gained effective and lasting clinical benefits from the immune-checkpoint inhibition therapy which targeting for PD-1/PD-L1. The detection of PD-L1 is a key link in the treatment of immune checkpoint inhibitors, but its detection methods and criteria in breast cancer have not been unified. This paper reviewed the detection methods of PD-L1 and its expression in subtypes of breast cancer.